Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model.
|
30273070 |
2018 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We further show that class I HDACi induce senescence in pancreatic cancer cells with mutant p53.
|
27838375 |
2017 |
Malignant neoplasm of pancreas
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
Enhanced phosphorylation of p53 by microRNA-26a leading to growth inhibition of pancreatic cancer.
|
26189069 |
2015 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
In contrast, all animals with CI-lacking TP53 developed various subtypes of PC, including acinar cell carcinoma, ductal adenocarcinoma, sarcomatoid carcinoma and neuroendocrine tumors, and all died within 65 weeks.
|
27991926 |
2017 |
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis.
|
24486587 |
2014 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Previous findings have shown that the tumor suppressor p53 is involved in the development of various types of cancer, including pancreatic cancer.
|
26531836 |
2016 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
|
17659731 |
2007 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Tests for mutant TP53 might be developed to improve the diagnosis of and screening for pancreatic cancer and high-grade dysplasia.
|
23200980 |
2013 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer.
|
19443408 |
2009 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We investigated four selected polymorphisms in TP53 (rs17878362:A(1)>A(2), rs1042522:G>C, rs12947788:C>T and rs17884306:G>A) in association with pancreatic cancer risk in a case-control study, including 240 cases and controls (for a total of 1827 individuals) from the Czech Republic.
|
20110284 |
2010 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Therapeutic targets of interest include mutated molecules that predispose to pancreatic cancer such as KRAS and TP53.
|
23436799 |
2013 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Most of the genes listed are responsible for various well-defined cancer syndromes, such as CDKN2A (familial atypical mole-multiple melanoma, FAMMM), the mismatch repair genes (Lynch Syndrome), TP53 (Li-Fraumeni syndrome), APC (familial adenomatous polyposis), and BRCA2 (breast-ovarian familial cancer), where PC is part of the cancer spectrum of the disease.
|
19150414 |
2009 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In pancreatic cancer mutations in oncogenes and tumor suppressor genes are frequently detected in p53 and K-ras.
|
8862512 |
1996 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutations in p53 have been documented in >50% of pancreatic cancers.
|
26592447 |
2016 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy.
|
29211796 |
2017 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
In vitro, Zyflamend inhibited the proliferation of pancreatic cancer cell lines regardless of p53 status and also enhanced gemcitabine-induced apoptosis.
|
21935918 |
2012 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The concomitant expression of oncogenic Kras(G12D) and mutant p53 (Trp53(R172H)) in the murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genes required for tumor progression.
|
22158044 |
2012 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer.
|
27637888 |
2017 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
One of the antibodies, CM1, recognises p53 in formalin-fixed, paraffin-embedded archival material and using this reagent we found immunodetectable p53 in 28 of 124 (23%) pancreatic cancers.
|
1764370 |
1991 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Our results indicate that mutated K-ras and p53 genes can cooperate in the establishment of ductal pancreatic cancers, whereas other genetic events have to be present in nonductal tumors.
|
8137263 |
1994 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Concurrent loss of p53 and K-ras function may contribute to the clinical aggressiveness of pancreas cancer.
|
9219065 |
1997 |
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
The circadian clock gene Bmal1 acts as a potential anti-oncogene in pancreatic cancer by activating the p53 tumor suppressor pathway.
|
26683776 |
2016 |
Malignant neoplasm of pancreas
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer.
|
12171884 |
2002 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The hypothesis in question can be tested if the DNA of P. gingivalis or the antibodies against P. gingivalis can be detected in patients with the p53 arginine mutation.If this hypothesis is true, it could reveal the real cause of pancreatic cancer, which is a fatal disease.
|
26617937 |
2015 |
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Frequently reported genome alterations were: the +3q27 and +8q24 mutations of TP53 for esophageal cancer; +20q13 for gastric cancer; -18q22 and +20q12-q13 mutations of APC, TP53 and KRAS for colorectal cancer, and the -18q22 mutation of KRAS and TP53 for pancreatic cancer.
|
19023234 |
2008 |